Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 34, No. 4, 2011
Issue release date: June 2011
Section title: Paper
Kidney Blood Press Res 2011;34:261–268
(DOI:10.1159/000326903)

Vitamin D and Vascular Calcification in Chronic Kidney Disease

Rodriguez M. · Martinez-Moreno J.M. · Rodríguez-Ortiz M.E. · Muñoz-Castañeda J.R. · Almaden Y.
Unidad de Investigación, Servicio de Nefrología, Red in ren, Instituto Maimónides de Investigación Biomédica de Córdoba, Departamento de Medicina, Hospital Universitario Reina Sofia, Córdoba, España
email Corresponding Author

Dr. Mariano Rodríguez

Unidad de Investigación, Hospital Reina Sofía

Avenida Menéndez Pidal s/n

ES–14004 Córdoba (Spain)

Tel. +34 95 701 0440, E-Mail juanm.rodriguez.sspa@juntadeandalucia.es


References

  1. Wilson PWF, Kauppila LI, O’Donnell CJ, Kiel DP, Hannan M, Polak JM, Cupples LA: Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001;103:1529–1534.
  2. London GM, Guerin AP, Marchais S, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant2003;18:1731–1740.
  3. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease.Hypertension 2001;38:938–942.
  4. Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW, Kroon AA: Vascular calcifications as a marker of increased cardiovascular risk: a meta analysis. Vasc Health Risk Manag2009;5:185–197.
  5. Vattikuti R, Towler DA: Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab 2004;286:E686–E696.
  6. Goodman WG: The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial 2004;17:209–216.
  7. Li X, Speer MY, Yang H, Bergen J, Giachelli CM: Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Thromb Vasc Biol 2010;30:321–326.
  8. Bikle DD: Vitamin D: an ancient hormone. Exp Dermatol 2010;20:7–13.
    External Resources
  9. Zitterman A, Schleithoff S Koerfer R: Vitamin D and vascular calcification. Curr Opin Lipidol 2007;18:41–46.
  10. Razzaque MS: The dualistic role of vitamin D in vascular calcifications. Kidney Int 2011;79:708–714.
  11. Sage AP, Tintut Y, Demer LL: Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 2010;7:528–536.
  12. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM: Exploring the biology of vascular calcification in chronic kidney disease: what’s circulating? Kidney Int 2008;73:384–390.
  13. Demer LL, Tintut Y: Vascular calcification: pathobiology of multifaceted disease. Circulation 2008;117:2938–2948.
  14. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM: Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001;89:1147–1154.
  15. Lau WL, Festing MH, Giachelli CM: Phosphate and vascular calcification: emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost. 2010;104:464–470.
  16. Schlieper G, Aretz A, Verberckmoes SC, Krüger T, Behets GJ, Ghadimi R, Weirich TE, Rohrmann D, Langer S, Tordoir JH, Amann K, Westenfeld R, Brandenburg VM, D’Haese PC, Mayer J, Ketteler M, McKee MD, Floege J: Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol 2010;21:689–696.
  17. Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, Rees L, Shanahan CM: Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010;21:103–112.
  18. Sage AP, Lu J, Tintut Y, Demer LL: Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int 2011;79:414–422.
  19. Speer MY, Li X, Hiremath PG, Giachelli CM: Runx2/Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis. J Cell Biochem 2010;110:935–947.
  20. Olgaard K, Salusky IB, Silver J: The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. Oxford, Oxford University Press, 2010, vol 18, pp 304–307.
  21. Moe SM, Reslerova M, Ketteler M, O’Neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX: Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005;67:2295–2304.
  22. Cranenburg EC, Vermeer C, Koos R, Boumans ML, Hackeng TM, Bouwman FG, Kwaijtaal M, Brandenburg VM, Ketteler M, Schurgers LJ: The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res 2008;45:427–436.
  23. Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, Schurgers LJ, Singhal A, Merryweather I, Brogan P, Shanahan C, Deanfield J, Rees L: The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008;23:3263–3271.
  24. Davies MR, Lund RJ, Hruska KA: BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 2003;14:1559–1567.
  25. Kang YH, Jin JS, Yi DW, Son SM: Bone morphogenetic protein-7 inhibits vascular calcification induced by high vitamin D in mice. Tohoku J Exp Med 2010;221:299–307.
  26. O’Neill WC, Lomashvili KA, Malluche HH, Faugere MC, Riser BL: Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 2011;79:512–517.
  27. Schlieper G, Westenfeld R, Krüger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, Djuric Z, Damjanovic T, Ketteler M, Vermeer C, Dimkovic N, Floege J, Schurgers LJ: Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011;22:387–395.
  28. El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, Ingalls CM, Liao HW, Giachelli CM: Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009;75:1297–1307.
  29. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004;15:2857–2867.
  30. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10–E17.
  31. Villa-Bellosta R, Sorribas V: Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calcium-phosphate deposition. Arterioscler Thromb Vasc Biol 2009;29:761–766.
  32. Villa-Bellosta R, Millan A, Sorribas V: Role of calcium-phosphate deposition in vascular smooth muscle cell calcification. Am J Physiol Cell Physiol 2011;300:C210–C220.
  33. Prosdocimo DA, Wyler SC, Romani AM, O’Neill WC, Dubyak GR: Regulation of vascular smooth muscle cell calcification by extracellular pyrophosphate homeostasis: synergistic modulation by cyclic AMP and hyperphosphatemia. Am J Physiol Cell Physiol 2010;298:C702–C713.
  34. Montes de Oca A, Madueño JA, Martinez-Moreno JM, Guerrero F, Muñoz-Castañeda J, Rodriguez-Ortiz ME, Mendoza FJ, Almaden Y, Lopez I, Rodriguez M, Aguilera-Tejero E: High-phosphate-induced calcification is related to SM22α promoter methylation in vascular smooth muscle cells. J Bone Miner Res 2010;25:1996–2005.
  35. Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, Akizawa T: Vitamin D and vascular calcification in chronic kidney disease. Bone 2009;45:S26–S29.
  36. Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V, Espe K, Dekker F, Brandenburg V, März W, Ritz E, Wanner C: Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010;31:2253–2261.
  37. Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM: Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860–866.
  38. Bas A, Lopez I, Perez J, Rodriguez M, Aguilera-Tejero E: Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res 2006;21:484–490.
  39. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E: Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007;72:709–715.
  40. Hirata M, Katsumata K, Endo K, Fukushima N, Ohkawa H, Fukagawa M: In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol Dial Transplant 2003;18:1770–1776.
  41. Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M: Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006;17:795–804.
  42. Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D: 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1370–1377.
  43. Zebger-Gong H, Müller D, Diercke M, Haffner D, Hocher B, Verberckmoes S, Schmidt S, D’Haese PC, Querfeld U: 1,25-Dihydroxyvitamin D3-induced aortic calcifications in experimental uremia: up-regulation of osteoblast markers, calcium-transporting proteins and osterix. J Hypertens 2011;29:339–348.
  44. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD: Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007;18:2116–2124.
  45. Lopez I, Mendoza FJ, Guerrero F, Almaden Y, Henley C, Aguilera-Tejero E, Rodriguez M: The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. Am J Physiol Renal Physiol 2009;296:F1376–F1385.
  46. Inoue T, Kawashima H: 1,25-Dihydroxyvitamin D3 stimulates 45Ca2+-uptake by cultured vascular smooth muscle cells derived from rat aorta. Biochem Biophys Res Commun 1988;152:1388–1394.
  47. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E: Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007;72:709–715.
  48. Koleganova N, Piecha G, Ritz E, Schmitt CP, Gross ML: A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 2009;75:60–71.
  49. Jono S, Nishizawa Y, Shioi A, Morii H: 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998;98:1302–1306.
  50. Rebsamen MC, Sun J, Norman AW, Liao JK: 1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002;91:17–24.
  51. Mesquita M, Demulder A, Wolff F, Mélot C, Damry N, Dratwa M, Bergmann P: Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease. Transplant Proc 2010;42:3444–3449.
  52. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943–1951.
  53. London GM: Awareness of vascular calcification alters mineral metabolism management. Semin Dial 2010;23:267–270.
  54. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA: Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008;19:1509–1519.
  55. Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ, Hiorns MP, Deanfield JE, Rees L: A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008;19:1239–1246.
  56. O’Neill WC, Lomashvili KA: Recent progress in the treatment of vascular calcification. Kidney Int 2010;78:1232–1239.
  57. Cunningham J, Zehnder D: New vitamin D analogs and changing therapeutic paradigms. Kidney Int 2011;79:702–707.
  58. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446–456.
  59. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M: The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008;73:300–307.
  60. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, Coll B, Fernandez E, Valdivielso JM: RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009;104:1041–1048.
  61. Noonan W, Koch K, Nakane M, Ma J, Dixon D, Bolin A, Reinhart G: Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant 2008;23:3824–3830.
  62. Sugiura S, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Sendo S, Hamaguchi K, Nagaya H, Tatematsu M, Kurata K, Yuzawa Y, Matsuo S: Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol 2010;14:43–50.
  63. Issa LL, Leong GM, Sutherland RL, Eisman JA: Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J Bone Miner Res 2002;17:879–890.